Envestnet Asset Management Inc. Sells 527 Shares of Haemonetics Co. (NYSE:HAE)

Envestnet Asset Management Inc. trimmed its position in shares of Haemonetics Co. (NYSE:HAEGet Rating) by 2.1% in the 2nd quarter, Holdings Channel.com reports. The firm owned 24,189 shares of the medical instruments supplier’s stock after selling 527 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Haemonetics were worth $1,577,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of HAE. Mutual of America Capital Management LLC boosted its holdings in shares of Haemonetics by 2.0% in the first quarter. Mutual of America Capital Management LLC now owns 46,613 shares of the medical instruments supplier’s stock worth $2,947,000 after acquiring an additional 906 shares during the period. Victory Capital Management Inc. boosted its holdings in shares of Haemonetics by 527.3% in the first quarter. Victory Capital Management Inc. now owns 41,516 shares of the medical instruments supplier’s stock worth $2,426,000 after acquiring an additional 34,898 shares during the period. State of Michigan Retirement System boosted its holdings in shares of Haemonetics by 1.7% in the first quarter. State of Michigan Retirement System now owns 12,974 shares of the medical instruments supplier’s stock worth $820,000 after acquiring an additional 218 shares during the period. Royce & Associates LP boosted its holdings in shares of Haemonetics by 6.9% in the first quarter. Royce & Associates LP now owns 757,244 shares of the medical instruments supplier’s stock worth $47,873,000 after acquiring an additional 49,136 shares during the period. Finally, Rice Hall James & Associates LLC boosted its holdings in shares of Haemonetics by 32.4% in the first quarter. Rice Hall James & Associates LLC now owns 76,645 shares of the medical instruments supplier’s stock worth $4,845,000 after acquiring an additional 18,766 shares during the period. 98.51% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on HAE. Citigroup raised their price target on Haemonetics from $80.00 to $88.00 and gave the stock a “neutral” rating in a report on Tuesday, November 8th. JMP Securities increased their price objective on Haemonetics from $90.00 to $105.00 and gave the stock a “market outperform” rating in a research report on Tuesday, November 8th. TheStreet upgraded Haemonetics from a “c+” rating to a “b” rating in a research report on Monday, November 7th. StockNews.com began coverage on Haemonetics in a research report on Wednesday, October 12th. They issued a “buy” rating on the stock. Finally, Mizuho increased their price objective on Haemonetics from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, November 8th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average price target of $96.17.

Haemonetics Trading Up 1.3 %

NYSE HAE opened at $79.93 on Monday. The stock’s 50-day simple moving average is $78.40 and its two-hundred day simple moving average is $70.54. Haemonetics Co. has a twelve month low of $43.50 and a twelve month high of $86.48. The company has a quick ratio of 1.76, a current ratio of 2.73 and a debt-to-equity ratio of 1.04. The company has a market capitalization of $4.05 billion, a price-to-earnings ratio of 48.15 and a beta of 0.40.

Insider Buying and Selling at Haemonetics

In other Haemonetics news, EVP Michelle L. Basil sold 11,448 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $78.36, for a total transaction of $897,065.28. Following the sale, the executive vice president now owns 32,635 shares in the company, valued at $2,557,278.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, EVP Michelle L. Basil sold 11,448 shares of Haemonetics stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $78.36, for a total value of $897,065.28. Following the transaction, the executive vice president now owns 32,635 shares in the company, valued at $2,557,278.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Michelle L. Basil sold 33,798 shares of Haemonetics stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $77.89, for a total value of $2,632,526.22. Following the completion of the transaction, the executive vice president now owns 35,395 shares in the company, valued at approximately $2,756,916.55. The disclosure for this sale can be found here. Insiders have sold 45,713 shares of company stock worth $3,566,256 over the last 90 days. Corporate insiders own 1.65% of the company’s stock.

Haemonetics Profile

(Get Rating)

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Featured Articles

Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAEGet Rating).

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.